Characteristics of patients with PFS greater than 12 months
| Age (y)/gender . | Histologic subtype of HL (stage) . | Percent CD30+ malignant cells . | Baseline SPD (cm2) . | Number of treatment cycles . | Number of dose delays (dose reduced to 1.2 mg/kg) . | Best clinical response (first observed) . | Reason for EOT . | Time off treatment (mo) . | PFS (mo) . |
|---|---|---|---|---|---|---|---|---|---|
| 71/F | Mixed cellularity (IIa) | 100 | 28.7 | 23 | 2 (cycle 10) | CR (cycle 2) | Investigator decision* | 2.7 | 22.3+ |
| 76/F | Mixed cellularity (IVb) | 20 | 12.9 | 16 | 0 (cycle 16) | CR (cycle 4) | AE (PSN) | 5.7 | 16.8+ |
| 64/F | Classical HL NOS (IIb) | 90 | 5.0 | 6† | 0 (no reduction) | CR (EOT) | AE (PSN) | 12.2 | 16.3+ |
| 84/M | Nodular sclerosis (IIIa) | 100 | 37.3 | 15 | 3 (cycle 6) | CR (cycle 2) | AE (PSN) | 1.0 | 14.3+ |
| 84/M | Classical HL NOS (IIIa) | 80 | 14.7 | 9 | 3 (cycle 4) | CR (cycle 2) | AE (PSN) | 7.4 | 14.3‡ |
| 78/M | Nodular sclerosis (IIa) | 90 | 64.4 | 5 | 0 (no reduction) | CR (EOT) | AE (orthostatic hypertension) | 9.8 | 13.4+ |
| Age (y)/gender . | Histologic subtype of HL (stage) . | Percent CD30+ malignant cells . | Baseline SPD (cm2) . | Number of treatment cycles . | Number of dose delays (dose reduced to 1.2 mg/kg) . | Best clinical response (first observed) . | Reason for EOT . | Time off treatment (mo) . | PFS (mo) . |
|---|---|---|---|---|---|---|---|---|---|
| 71/F | Mixed cellularity (IIa) | 100 | 28.7 | 23 | 2 (cycle 10) | CR (cycle 2) | Investigator decision* | 2.7 | 22.3+ |
| 76/F | Mixed cellularity (IVb) | 20 | 12.9 | 16 | 0 (cycle 16) | CR (cycle 4) | AE (PSN) | 5.7 | 16.8+ |
| 64/F | Classical HL NOS (IIb) | 90 | 5.0 | 6† | 0 (no reduction) | CR (EOT) | AE (PSN) | 12.2 | 16.3+ |
| 84/M | Nodular sclerosis (IIIa) | 100 | 37.3 | 15 | 3 (cycle 6) | CR (cycle 2) | AE (PSN) | 1.0 | 14.3+ |
| 84/M | Classical HL NOS (IIIa) | 80 | 14.7 | 9 | 3 (cycle 4) | CR (cycle 2) | AE (PSN) | 7.4 | 14.3‡ |
| 78/M | Nodular sclerosis (IIa) | 90 | 64.4 | 5 | 0 (no reduction) | CR (EOT) | AE (orthostatic hypertension) | 9.8 | 13.4+ |
EOT, end of treatment; PSN, peripheral sensory neuropathy; SPD, sum of the products of the largest diameters of up to 6 index lymph nodes or nodal masses being followed for response assessment.
No definite evidence of lymphoma after 23 cycles.
Consolidative radiation after EOT.
Death due to respiratory failure 8 months after the last dose of brentuximab vedotin; preexisting coronary artery disease, myelofibrosis, and macrocytic anemia.